Nitric oxide treatment reduces neo-intimal formation and modulates osteopontin expression in an ex-vivo human model of intimal hyperplasia

Cytokine

Volumn 46, Issue 2, 2009, Pages 228-235

  Colotti, Chiara ^a   Vittorini, Simona ^b   Ottaviano, Virginia ^c   Maltinti, Maristella ^b   Angeli, Valeria ^b   Ry, Silvia Del ^b   Giannessi, Daniela ^b  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Interleukin 6; Intimal hyperplasia; Nitric oxide; Osteopontin; Restenosis

Indexed keywords

CYTOKINE; INTERLEUKIN 6; NITRIC OXIDE; NITRITE REDUCTASE; OSTEOPONTIN;

ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DRUG EFFECT; EX VIVO STUDY; HUMAN; HUMAN TISSUE; INTIMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SAPHENOUS VEIN; SIGNAL TRANSDUCTION; TISSUE CULTURE;

GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERPLASIA; INTERLEUKIN-6; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; OSTEOPONTIN; SAPHENOUS VEIN; STENTS; TISSUE CULTURE TECHNIQUES; TUNICA INTIMA;

EID: 65049089884     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.02.002     Document Type: Article

References (40)

1. Nordmann A.J., Briel M., and Bucher H.C. Mortality in randomized controlled clinical trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta analysis. Eur Heart J 27 (2006) 2784-2814
2. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., Rickenbacher P., Hunziker P., Mueller C., et al. For the BASKET-LATE investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. J Am Coll Cardiol 48 (2006) 2584-2591
3. Hodgson J.M., Stone G.W., Lincoff A.M., Klein L., Walpole H., Bottner R., et al. Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the society for cardiovascular angiography and interventions drug-eluting stent task force. Catheter Cardiovasc Interv 69 (2007) 327-333
4. Stettler C., Wandel S., Allemann S., Castrati A., Morice M.C., Schomig A., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
5. Babapulle M.N., Joseph L., Belisle P., Brophy J.M., and Eisenberg M.J. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364 (2004) 583-591
6. Kastrati A., Mehilli J., von Beckerarth N., Dibra A., Hausleiter J., Pache J., et al. ISAR-DESIRE Study Investigators. Sirolimus eluting stent or paclitaxel eluting stent vs. ballon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293 (2005) 165-171
7. Van Belle E., Susen S., Jude B., and Bertrand M.E. Drug-eluting stents: trading restenosis for thrombosis?. J Thromb Haemost 5 Suppl 1 (2007) 238-245
8. Maisel W.H. Unanswered questions-drug-eluting stents and the risk of late thrombosis. N Engl J Med 356 (2007) 981-984
9. Nakazawa G., Finn A.V., and Virmani R. Vascular pathology of drug-eluting stents. Herz 32 (2007) 274-280
10. Costa M.A., and Simon D.I. Molecular basis of restenosis and drug eluting stents. Circulation 111 (2005) 2257-2273
11. Steffel J., and Tanner F.C. Biological effects of drug-eluting stents in the coronary circulation. Herz 32 (2007) 268-273
12. Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladich E., et al. Pathology of drug eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
13. Panda D., Kundu G.C., Lee B.I., Peri A., Fohl D., Chackalaparampil I., et al. Potential roles of osteopontin and αVβ3 integrin in the development of coronary artery restenosis after angioplasty. Proc Natl Acad Sci USA 94 (1997) 9308-9313
14. Giachelli C.M., Schwartz S.M., and Liaw L. Molecular and cellular biology of osteopontin. Potential role in cardiovascular disease. Trends Cardiovasc Med 5 (1995) 88-95
15. Isoda K., Nishikawa K., Kamezawa Y., Yoshida M., Kusuhara M., Moroi M., et al. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res 91 (2002) 77-82
16. Denhardt D.T., Noda M., O'Regan A.W., and Pavlin D. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodelling, and cell survival. J Clin Invest 107 (2001) 1055-1061
17. Standal T., Borset M., and Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodelling. Exp Oncol 26 (2004) 179-184
18. Janero D.R., and Ewing J.F. Nitric oxide and post-angioplasty restenosis: pathological correlates and therapeutic potential. Free Radical Biol Med 29 (2000) 1121-1199
19. Mitra A.K., Gangahar D.M., and Agrawal D.K. Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia. Immunol Cell Biol 84 (2006) 115-124
20. Soyombo A.A., Angelini G.D., Bryan A.J., and Newby A.C. Surgical preparation induces injury and promotes smooth muscle cell proliferation in a culture of human saphenous vein. Cardiovasc Res 27 (1993) 1961-1967
21. Rodrigo M.C., Martin D.S., Redetzke R.A., and Eyster K.M. A method for the extraction of high-quality RNA and protein from single small samples of arteries and veins preserved in RNA later. J Pharmacol Toxicol Methods 47 (2002) 87-92
22. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
23. Gadeau A.P., Campan M., Millet D., Candresse T., and Desgranges C. Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler Thromb 13 (1993) 120-125
24. Matsui Y., Rittling S.R., Okamoto H., Inobe M., Jia N., Shimizu T., et al. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 23 (2003) 1029-1034
25. Zalewski A., and Shi Y. Vascular myofibroblasts. Lessons from coronary repair and remodelling. Arterioscler Thromb Vasc Biol 17 (1997) 417-422
26. Seino Y., Ikeda U., Ikeda M., Yamamoto K., Misawa Y., Hasegawa T., et al. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 6 (1994) 87-91
27. Rus H.G., Vlaicu R., and Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 127 (1996) 263-271
28. Hojo Y., Ikeda U., Katsuki T., Mizuno O., Fukazawa H., Kurosaki K., et al. Interleukin-6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 84 (2000) 83-87
29. Agnihotri R., Crawford H.C., Haro H., Matrisian L.M., Havrda M.C., and Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 276 (2001) 28261-28267
30. Scatena M., Liaw L., and Giacchelli C.M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27 (2007) 2302-2309
31. Bendeck M.P., Irvin C., Reidy M., Smith L., Mulholland D., Horton M., et al. Smooth muscle cell matrix metalloproteinase production is stimulated via alpha(v)beta(3) integrin. Arterioscler Thromb Vasc Biol 20 (2000) 1467-1472
32. Colotti C., Angeli V., Del Ry S., Maltinti M., Vittorini S., and Giannessi D. Matrix metalloprotease-2 and -9 concentration and activity in serum and culture medium samples: a methodological reappraisal. Clin Chem Lab Med 45 (2007) 1292-1298
33. Bult H. Restenosis: a challenge for pharmacology. Trends Pharmacol Sci 21 (2000) 274-279
34. Know M.H., Yamaguchi A., Jahncke C.L., Miniati D., Murata S., Grunenfelder J., et al. l-Arginine polymers inhibit the development of vein graft neointimal hyperplasia. J Thorac Cardiovasc Surg 121 (2001) 971-980
35. Chaux A., Ruan X.M., Fishbein M.C., Ouyang Y., Kaul S., Pass J.A., et al. Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein graft implanted in the arterial circulation. J Thorac Cardiovasc Surg 115 (1998) 604-612
36. Pearce C.G., Najjar S.F., Kapadia M.R., Murar J., Eng J., Lyle B., et al. Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. Free Radical Biol Med 44 (2008) 73-81
37. Ahanchi S.S., Tsihlis N.D., and Kibbe M.R. The role of nitric oxide in the pathophysiology of intimal hyperplasia. J Vasc Surg 45 (2007) A64-A73
38. Guo H., Cai C.Q., Schroeder R.A., and Kuo P.C. Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. J Immunol 166 (2001) 1079-1086
39. Leali D., Moroni E., Bussolino F., and Presta M. Osteopontin overexpression inhibits in vitro re-endothelialization via integrin engagement. J Biol Chem 282 (2007) 19676-19684
40. Cooney R., Hynes S.O., Sharif F., Howard L., and O'Brien T. Effect of gene delivery of NOS isoforms on intimal hyperplasia and endothelial regeneration after balloon injury. Gene Ther 14 (2007) 396-404